Incidence and Management of Ocular Hypertension Following the 0.18 mg Fluocinolone Acetonide Implant for Non-infectious Uveitis affecting the Posterior Segment.
Publication/Presentation Date
9-10-2026
Abstract
PURPOSE: To investigate the real-world incidence and management of ocular hypertension (OHT) following intravitreal 0.18mg fluocinolone acetonide implant (FAi, Yutiq) for non-infectious uveitis affecting the posterior segment (NIU-PS).
METHODS: Retrospective review of eyes treated with 0.18 mg FAi (2019-2025) with ≥1 month follow-up. Primary outcome was OHT (IOP >24 mmHg). Secondary outcomes included IOP ≥30 mmHg, >12 mmHg IOP increase from baseline, and OHT treatment.
RESULTS: A total of 275 FAi-treated eyes (178 patients, mean age: 62.87 years) were included. Patients received an average of 1.05 FAi (range:1-2), with mean follow-up of 20.59 ± 0.72 months. Mean baseline IOP was 14.30 ± 3.90 mmHg. Glaucoma and OHT were present in 28.4% and 32.4% of eyes, respectively and 38.5% were on IOP-lowering therapy. Supplemental corticosteroid injections were required in 31.3%. The OHT rate after FAi was 10.5%. Elevated IOP ≥30 mmHg occurred in 5.82%. IOP >12 mmHg from baseline occurred in 7.3%. Among OHT eyes, 41.4% resolved with observation, 44.8% required topical therapy (mean 1.78 agents), and 10.3% required incisional surgery. Higher baseline IOP (adjusted OR 1.41 per 1 mmHg increase, 95% CI:1.19-1.67) and baseline IOP-lowering medication use (OR 8.56, 95% CI:2.61-28.11) were the strongest predictors of rise in IOP.
CONCLUSION: FAi for the treatment of NIU-PS was associated with low rates of OHT, reinforcing its safety. Eyes with higher baseline IOP and those on prior IOP-lowering medications had a substantially increased risk of OHT, highlighting the need for closer IOP monitoring in this subgroup.
ISSN
1539-2864
Published In/Presented At
Farrell, L. C., Gomes, I. V. Y., Zafar, S., Woods, M. M., Muste, J. C., Patel, H., Wibbelsman, T., Massenzio, S., Kim, J. S., Garg, S. J., Dunn, J. P., Hsu, J., Fell, D., & Deaner, J. D. (2026). Incidence and Management of Ocular Hypertension Following the 0.18 mg Fluocinolone Acetonide Implant for Non-infectious Uveitis affecting the Posterior Segment. Retina (Philadelphia, Pa.), 10.1097/IAE.0000000000005012. Advance online publication. https://doi.org/10.1097/IAE.0000000000005012
Disciplines
Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods
PubMedID
42720983
Department(s)
Administration and Leadership
Document Type
Article